NEW YORK (GenomeWeb News) – Cancer genome analysis firm Personal Genome Diagnostics said today that it will collaborate with Blueprint Medicines to search for novel kinase targets for cancer drugs.

Personal Genome Diagnostics will use exome sequencing as well as its own proprietary digital karyotyping technology, which it licensed from Johns Hopkins, to analyze copy number changes in cancer genomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.